30 closest matches · ranked by relevance
Fluid Loss · Blood Loss
Primary: Impact of Subject Positioning on Percent Change of Heart Rate (HR) After Minor Blood Loss (e.g., 500mL) — 10.7; 14.7 percent change
Healthy
Primary: Age-Dependent Change in Striatal 18F-DTBZ Uptake of Healthy Subjects. — 0.05 SUVR
Healthy
Primary: Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) — 21.48 U/L
Type1diabetes
Primary: Percentage of Time Spent With Dexcom CGMG < 60 mg/dl — 1.32; 1.95; 1.05; 0.99 percentage of time
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Diabetes Mellitus · Obesity
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (Safety and Tolerability) — 2; 1; 1; 3 Participants
Healthy Subjects Without Type 1 Diabetes
Primary: Overall Mean Sensor Glucose by Age Group — 98; 103; 97; 96 mg/dL — p=0.009
Photoreceptor Sensitivity Thresholds
Primary: Time to Rod-cone Break (RCB) — 11.34; 9.98 Minutes
Severe Renal Impairment
Primary: Area Under the Curve From 0 to Tau (AUC 0-t (ng*h/mL)) — 175; 145 nanogram hour per milliliter (ng•h/mL)
Diabetes Mellitus · Obesity
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability] — 2; 0; 0; 3 Participants
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Healthy Participants
Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants
Chikungunya Virus Infection
Primary: Frequency of Adverse Events (AEs) — 5; 3; 2; 3 Participants
Obesity · Endothelial Dysfunction · Decreased Vascular Flow
Primary: Myocardial Perfusion Reserve Measured by Quantitative Perfusion MRI (Ratio of Myocardial Blood Flow During Stress Over Myocardial Blood Flow at Rest) — 2.25; 2.44 ratio…
Fluid Loss
Primary: Characterize Changes in the Relative Index During an Apheresis Procedure — 94.9; 99.3 Relative Index
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 40.0; 75.0; 50.0; 75.0 Percentage of participants
Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Primary: Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations — 2.36; 17.71 ng/mL
Renal Impairment
Primary: Dose-Normalized Maximum Concentration of Plerixafor (Cmax) — 0.0452; 0.0388; 0.0490; 0.0475 ng/mL/ug
Intraosseous Vascular Access
Primary: Occurrences of Extravasation During Infusion — 2 participants
Healthy Adults
Primary: Safety (Evaluation of Adverse Events) — 17; 17 Participants
Post-operative Nausea and Vomiting
Primary: Mass Balance — 96.4 percent excreted
Clexane is Administered to Healthy Volunteers
Primary: Anti-FXa Cmax — 0.999; 0.926 IU/mL
Alzheimer Disease
Primary: Plasma CT1812 Concentration at 96 Hours Timepoint — 0.0000707 μg/mL
Classic Galactosemia
Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 0; 0; 2 Participants
Healthy Volunteers · Adult · Pharmacokinetics
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…
Healthy
Primary: Slope of the Placebo-corrected Change From Baseline of Heart Rate at Rest and Plasma Concentration Between 0 to 10 Hours — 0.80; 5.46 beats/min
Multi-drug Resistant Tuberculosis
Primary: Relative Bioavailability - Cmax — 2170; 1180; 1850; 1090 ng/mL — p=0.0001
Healthy
Primary: Change in Intact FGF23 — 1.001; 1.006; 1.009; 1.005 pg/ml — p=0.3738